149 related articles for article (PubMed ID: 15517913)
1. Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy.
Hsu CH; Hsu HC; Chen HL; Gao M; Yeh PY; Chen PJ; Cheng AL
Anticancer Res; 2004; 24(5A):3035-40. PubMed ID: 15517913
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
3. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.
Alexopoulou A; Theodorou M; Dourakis SP; Karayiannis P; Sagkana E; Papanikolopoulos K; Archimandritis AJ
J Viral Hepat; 2006 Sep; 13(9):591-6. PubMed ID: 16907845
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study.
Yeo W; Chan PK; Hui P; Ho WM; Lam KC; Kwan WH; Zhong S; Johnson PJ
J Med Virol; 2003 Aug; 70(4):553-61. PubMed ID: 12794717
[TBL] [Abstract][Full Text] [Related]
6. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
Endo T; Sakai T; Fujimoto K; Yamamoto S; Takashima H; Haseyama Y; Nishio M; Koizumi K; Koike T; Sawada K
Bone Marrow Transplant; 2001 Feb; 27(4):433-6. PubMed ID: 11313673
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro.
Vincent IE; Lucifora J; Durantel D; Hantz O; Chemin I; Zoulim F; Trepo C
Antivir Ther; 2009; 14(1):131-5. PubMed ID: 19320247
[TBL] [Abstract][Full Text] [Related]
8. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect of radiation and interleukin-6 on hepatitis B virus reactivation in liver through STAT3 signaling pathway.
Chou CH; Chen PJ; Jeng YM; Cheng AL; Huang LR; Cheng JC
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1545-52. PubMed ID: 19327909
[TBL] [Abstract][Full Text] [Related]
10. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.
Vassiliadis T; Garipidou V; Tziomalos K; Perifanis V; Giouleme O; Vakalopoulou S
Am J Hematol; 2005 Nov; 80(3):197-203. PubMed ID: 16247746
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration.
Dai MS; Wu PF; Shyu RY; Lu JJ; Chao TY
Liver Int; 2004 Dec; 24(6):540-6. PubMed ID: 15566502
[TBL] [Abstract][Full Text] [Related]
12. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of multiple gene expression and virus replication of HBV by stable RNA interference in 2.2.15 cells.
Ren X; Luo G; Xie Z; Zhou L; Kong X; Xu A
J Hepatol; 2006 Apr; 44(4):663-70. PubMed ID: 16466826
[TBL] [Abstract][Full Text] [Related]
14. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
Kohmoto M; Enomoto M; Tamori A; Habu D; Takeda T; Kawada N; Sakaguchi H; Seki S; Shiomi S; Nishiguchi S
J Med Virol; 2005 Feb; 75(2):235-9. PubMed ID: 15602726
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy of siRNAs mediates greater suppression on hepatitis B virus cccDNA in HepG2.2.15 cell.
Xin XM; Li GQ; Guan XR; Li D; Xu WZ; Jin YY; Gu HX
Hepatogastroenterology; 2008; 55(88):2178-83. PubMed ID: 19260501
[TBL] [Abstract][Full Text] [Related]
16. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection.
Kohrt HE; Ouyang DL; Keeffe EB
Clin Liver Dis; 2007 Nov; 11(4):965-91, x. PubMed ID: 17981237
[TBL] [Abstract][Full Text] [Related]
17. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
Yeo W; Chan PK; Ho WM; Zee B; Lam KC; Lei KI; Chan AT; Mok TS; Lee JJ; Leung TW; Zhong S; Johnson PJ
J Clin Oncol; 2004 Mar; 22(5):927-34. PubMed ID: 14990649
[TBL] [Abstract][Full Text] [Related]
18. The short hairpin RNA driven by polymerase II suppresses both wild-type and lamivudine-resistant hepatitis B virus strains.
Ren GL; Fang Y; Ma HH; Lei YF; Wang D; Xu MC; Wang PZ; Huang CX; Nie OH; Sun YT; Bai XF
Antivir Ther; 2007; 12(6):865-76. PubMed ID: 17926641
[TBL] [Abstract][Full Text] [Related]
19. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.
Lalazar G; Rund D; Shouval D
Br J Haematol; 2007 Mar; 136(5):699-712. PubMed ID: 17338776
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy.
Schnepf N; Sellier P; Bendenoun M; Zini JM; Sanson-le Pors MJ; Mazeron MC
J Clin Virol; 2007 May; 39(1):48-50. PubMed ID: 17368969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
